Implementation
of Counterfeit Protection Systems
in the Pharmaceutical Industry
Objectives
The aim of this conference is to present both the regulatory authorities' activities and the pharmaceutical industry's activities to develop and establish appropriate counterfeit protection systems. The conference will focus on effective and affordable strategies, improve collaboration among regulators and pharmaceutical industry, and discuss actions in the global fight against counterfeit. |
Speakers
- Nimo Ahmed,
MHRA, UK
- Patricia Blanco,
ETCO, Brazil
- Hugo Bonar,
Irish Medicines Board, Ireland
- Andy Charvill,
MHRA, UK
- Frederick L. Fricke,
FDA, USA
- Jean-Michel Guirado,
Amgen, The Netherlands
- Prof Dr. Ulrike Holzgrabe,
University of Würzburg, Germany
- Dr Dries de Kaste,
RIVM, The Netherlands
- Dr Sabine Kopp,
WHO, Switzerland
- Dr Thomas Lenhard,
sanofi-aventis, Germany
- Dr Chris Oldenhof,
DSM Anti-Infectives, The Netherlands
- Dr Jim Rittenburg,
Authentix Inc., USA
- Dr Stephan Schwarze,
Bayer Schering Pharma AG, Germany
- Janice M. Soreth,
FDA, USA
- Nathalie Tallet,
sanofi-aventis, France
- Dr Christian Tillmanns,
meyer//meisterernst Rechtsanwälte, Germany
|
 Highlights
- Regulatory Updates
- WHO’s Anticounterfeiting
Programme and IMPACT
- EU Directive on Counterfeit and
the Council of Europe’s Draft
Convention
- MHRA (UK) Anticounterfeiting
Strategy
- FDA’s Activities
- Legal Obligations and Implications
for the Pharmaceutical
Industry
- The Pharmaceutical Tracing and Authentication System in
Brazil
- Analytical Detection of Counterfeit Drugs
- Advanced Forensic Techniques at FDA’s
Forensic Chemistry
Center
- Role of the MHRA (UK) Anticounterfeiting
Laboratory
- NIR and Raman Spectroscopy at the RIVM
(NL) Laboratory
- Missions and Role of Sanofi-Aventis’
Testing Laboratory
|
 |
